Recombinant Human IL-31 Protein, His Tag (MALS verified), 100 µg

Background
IL-31 is an inflammatory cytokine that helps trigger cell-mediated immunity against pathogens. Activates STAT3 and possibly STAT1 and STAT5 through the IL31 heterodimeric receptor composed of IL31RA and OSMR. It has also been identified as a major player in a number of chronic inflammatory diseases, including atopic dermatitis. May function in skin immunity. IL-31 is produced by a variety of cells, namely type 2 helper (TH2) T-cells. IL-31 sends signals through a receptor complex made of IL-31RA and oncostatin M receptor β (OSMRβ) expressed in immune and epithelial cells. These signals activate three pathways: ERK1/2 MAP kinase, PI3K/AKT, and JAK1/2 signaling pathways.

Source
Recombinant Human IL-31, His Tag (IL1-H5247) is expressed from human 293 cells (HEK293). It contains AA Ser 24 - Thr 164 (Accession # Q6EBC2-1).
Predicted N-terminus: His

Molecular Characterization
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 17.7 kDa. The protein migrates as 23-33 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "The IL-31/TRPV1 pathway mediates allergic asthma exacerbated by DINP dermal exposure in OVA-sensitized Balb/c mice"
Peng, Wu, Li et al
Sci Total Environ (2023)
(2) "Characterisation of the pruritus responses and pruritic behaviours in an interleukin 31-induced canine model of pruritus"
Pearson, Denley, Blubaugh et al
Vet Dermatol (2023)
(3) "Seladelpar treatment reduces interleukin-31 and pruritus in patients with primary biliary cholangitis"
Kremer, Mayo, Hirschfield et al
Hepatology (2023)
Showing 1-3 of 727 papers.